1 SNJBs Shriman Sureshdada Jain College of Pharmacy, Chandwad, Maharashtra, India.
2 KCTs R. G. Sapkal College of Pharmacy, Nashik, Maharashtra, India.
3 MGV's Samajshree Prashantdada Hiray College of Pharmacy, Malegaon, Maharashtra, India.
4 Matoshri College of Pharmacy, Mhasrul, Nashik, Maharashtra, India.
5 KCTs R. G. Sapkal Institute of Pharmacy, Anjneri, Nashik, Maharashtra, India.
Corresponding Author: V. R. Daga, Email: vandana.chandwad@gmail.com
Received: 20th Feb, 2026 | Revised: 4th Mar, 2026 | Accepted: 25th Mar, 2026 | Available Online: 10th Apr, 2026
This study's main goal was to develop a colon-targeted drug delivery system by combining excipients made using the spray drying method, like binders and fillers, into a single powder blend with better tableting qualities. The study investigates the co-processing of excipients with various functions using spray drying. Particle size, density, flowability, and compressibility were among the physicochemical and tableting characteristics of the excipient that were evaluated. Mesalamine, the master medication, was immediately compressed using spray-dried co-excipient. For the in vitro drug release studies, a pH 7.4 phosphate buffer and simulated intestinal and stomach contents were utilized. The formulation's release profile showed a sustained drug release in the intestinal fluid, indicating that the drug was delivered to the colon. Overall, the co-processed excipient-based formulation created utilizing the spray drying technique showed promising results in terms of its physicochemical properties and colon-targeted drug delivery. This work lays the groundwork for the creation of innovative drug delivery methods to treat a range of inflammatory diseases that impact the colon.
Keywords: Spray dryer, Co-excipient, Colon targets, Ulcerative colitis, pH dependent polymers.
How to cite this article: Daga VR, Shahare HV, Jadhav KR, Nahar PP, Dungarwal UN, Patil DP, Kapse SN, Shahare SH. Development and Characterization of a Spray-Dried Directly Compressible Co-Processed Excipient for Targeted Delivery of Mesalamine. Int J Drug Deliv Technol. 2026;16(4):536-540. DOI: 10.25258/ijddt.16.4.55
Source of support: Nil.
Conflict of interest: The authors declare no conflict of interest.